Clinical Trials Search
A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients with Platinum-Resistant Recurrent Ovarian Cancer
The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.
Primary Objective: To determine the maximum tolerated dose of PTX-200 when combined with carboplatin in a Phase IA clinical trial of women with platinum-resistant, recurrent or persistent OVCA. Secondary Objectives: a) To evaluate the clinical activity of carboplatin plus PTX-200 in women with recurrent/persistent, platinum-resistant OVCA in a phase IB clinical trial assessing response rate, progression-free survival, and duration of stable disease. b) To assess the effect of PTX-200 on phospho-Akt signaling, proliferation and apoptosis within circulating tumor cells. c) Correlative studies to determine baseline p-Akt expression and signaling within circulating tumor cells and the ability of PTX-200 to downregulate p-Akt signaling, inhibit proliferation, and induce apoptosis.